Sort
53,477 grants matching “addiction”
Oncogenic mechanisms and molecular targets in lymphoma
$1,263,868Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Oncogenic mechanisms and molecular targets in myeloma
$1,263,868Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
RNA interference-based screens for molecular targets in cancer
$1,263,868Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders
$1,263,814Lawrence C Kuo · Mebias Discovery, Inc. · UG3 · FY2019 · DA
Preservation of Proteomic Stability and Promotion of Protein Lipidation by HSF1
$1,263,691Chengkai Dai · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse
$1,263,356Tong H Lee · Duke University · RC2 · FY2010 · DA
Development of the OpiAID strength band platform
$1,262,922David Reeser · Opiaid, Inc. · R44 · FY2025 · DA
Developmemt of Novel Treatments for Nicotine Addiction
$1,262,846University Of Kentucky · U19 · FY2005 · DA
9/24- Healthy Brain and Child Development National Consortium
$1,262,462Lauren S Wakschlag · Northwestern University At Chicago · U01 · FY2023 · DA
NHGRI/DIR Technology Transfer Program
$1,261,312Eric Green · National Human Genome Research Institute · ZIK · FY2010 · HG
Neurobiology of Addiction Research Center (NARC)
$1,260,844Medical University Of South Carolina · P50 · FY2005 · DA
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
$1,260,610Steffanie A Strathdee · University Of California, San Diego · R01 · FY2022 · DA
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
$1,259,901Richard Joseph Johnson · Colorado Research Partners, Llc · U01 · FY2020 · AA
Prevention of Relapse in Addiction
$1,259,651Kenzie Preston · National Institute On Drug Abuse · ZIA · FY2014 · DA
Evaluation Of Treatments Of Opioid And Cocaine Dependence
$1,259,651Kenzie Preston · National Institute On Drug Abuse · ZIA · FY2014 · DA
TARGETING A NONONCOGENE ADDICTION TO THE AUTOCRINE SEMA3C GROWTH PATHWAY FOR THE TREATMENT OF LETHAL METASTATIC PROSTATE CANCER
$1,259,331The University Of British Columbia · · FY2021 · Department of the Army
Frontal striatal systems and dopamine in normal and pathological behavior
$1,258,395Bruno Averbeck · National Institute Of Mental Health · ZIA · FY2013 · MH
Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder
$1,258,359Adam Mariusz Bisaga · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · U01 · FY2020 · DA
Hypothalamic neuronal circuits controlling goal-directed behaviors
$1,258,000Yexica Aponte Moreno · National Institute On Drug Abuse · ZIA · FY2014 · DA
Stimulant Pharmacotherapy: Noradrenergic Targets
$1,257,829Thomas Richard Kosten · Baylor College Of Medicine · P50 · FY2012 · DA
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
$1,257,794James M Wachira · Morgan State University · U54 · FY2019 · MD
Neurobiology of Addiction Research Center (NARC)
$1,257,202Peter W Kalivas · Medical University Of South Carolina · P50 · FY2010 · DA
Disease Modeling Unit
$1,256,374Stephen A Murray · Jackson Laboratory · U54 · FY2020 · OD
The National Drug Abuse Treatment Clinical Trials Network (U10)
$1,255,594Roger D. Weiss · Mclean Hospital · U10 · FY2012 · DA
EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI. ASSESSMENT OF POTENTIAL SUBSTANCE ABUSE TREATMENT MEDICATIONS IN NONHUMAN PRIMATE
$1,255,555Mclean Hospital · N01 · FY2025 · DA